Cargando…

Clinical and epidemiological characteristics of severe community-acquired pneumonia in children after introduction of the 10-valent pneumococcal vaccine

BACKGROUND: Pneumonia is an important cause of morbimortality in Brazil, despite the extensive vaccination coverage and the socioeconomic improvement in the past years. OBJECTIVE: To describe the epidemiological and clinical characteristics of severe community-acquired pneumonia in children after th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lima, Eduardo JF, Mello, Maria JG, Albuquerque, Maria FPM, Lopes, Maria IL, Serra, George HC, Abreu-Lima, Maria AZ, Correia, Jailson B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683263/ https://www.ncbi.nlm.nih.gov/pubmed/29388602 http://dx.doi.org/10.2147/PHMT.S88132

Ejemplares similares

Risk factors for community-acquired pneumonia in children under five years of age in the post-pneumococcal conjugate vaccine era in Brazil: a case control study
por: Fonseca Lima, Eduardo Jorge da, et al.
Publicado: (2016)

Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children
por: da Silva, Sandra Rodrigues, et al.
Publicado: (2016)

Pneumococcal Carriage, Serotype Distribution, and Risk Factors in Children With Community-Acquired Pneumonia, 5 Years After Introduction of the 10-Valent Pneumococcal Conjugate Vaccine in Ethiopia
por: Negash, Abel Abera, et al.
Publicado: (2019)

Pneumococcal colonization and severity of pneumonia in hospitalized Cambodian children following introduction of the 13-valent pneumococcal conjugate vaccine
por: Miliya, Thyl, et al.
Publicado: (2023)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults
por: Isturiz, Raul, et al.
Publicado: (2015)

Prescription of antibiotics in community-acquired pneumonia in children: are we following the recommendations?
por: da Fonseca Lima, Eduardo Jorge, et al.
Publicado: (2016)

Increase of Macrolide-Resistance in Streptococcus pneumoniae Strains After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Lima, Peru
por: Gonzales, Brayan E., et al.
Publicado: (2022)

Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan
por: Takeuchi, N., et al.
Publicado: (2020)

Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain
por: Càmara, Jordi, et al.
Publicado: (2017)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
por: Adamu, Aishatu L., et al.
Publicado: (2023)

Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain
por: Domínguez, Àngela, et al.
Publicado: (2017)

Multiple Colonization with S. pneumoniae before and after Introduction of the Seven-Valent Conjugated Pneumococcal Polysaccharide Vaccine
por: Brugger, Silvio D., et al.
Publicado: (2010)

Effect of 10-Valent Pneumococcal Vaccine on Pneumonia among Children, Brazil
por: Afonso, Eliane Terezinha, et al.
Publicado: (2013)

Pneumococcal Carriage in Young Children One Year after Introduction of the 13-Valent Conjugate Vaccine in Italy
por: Camilli, Romina, et al.
Publicado: (2013)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
por: Hanquet, Germaine, et al.
Publicado: (2022)

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type Streptococcus pneumoniae
por: Chandler, Thomas, et al.
Publicado: (2022)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
por: Turner, Paul, et al.
Publicado: (2015)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
por: Patel, Sweta M., et al.
Publicado: (2022)

Evolution, Clinical and Microbiological Characteristics of Invasive Pneumococcal Disease since the Introduction of the Pneumococcal Conjugate Vaccine 13-Valent in Adults over 18 Years Old
por: Buades, Juan, et al.
Publicado: (2021)

Direct Effect of 10-Valent Conjugate Pneumococcal Vaccination on Pneumococcal Carriage in Children Brazil
por: Andrade, Ana Lucia, et al.
Publicado: (2014)

1100 Notable Serotype Replacement of Invasive Streptococcus pneumoniae in Kagoshima, Japan, after the Sequential Introduction of 7-valent and 13-valent Pneumococcal Conjugate Vaccines
por: Nishi, Junichiro, et al.
Publicado: (2014)

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
por: Reyburn, R., et al.
Publicado: (2022)

Serotype Distribution of Clinical Streptococcus pneumoniae Isolates before the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Cambodia
por: Inghammar, Malin, et al.
Publicado: (2018)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
por: Shen, Ching-Fen, et al.
Publicado: (2021)

Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: Knol, Mirjam J., et al.
Publicado: (2015)

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia
por: ELEMRAID, M. A., et al.
Publicado: (2013)

Changes in Serotype of Streptococcus pneumoniae After the Introduction of the 13-Valent Pneumococcal Vaccine in a Homogenous Population on Jeju Island
por: Yoo, Jeong Rae, et al.
Publicado: (2019)

Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

Pneumococcal carriage in households in Karonga District, Malawi, before and after introduction of 13-valent pneumococcal conjugate vaccination
por: Heinsbroek, Ellen, et al.
Publicado: (2018)

Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use
por: Baxter, Roger, et al.
Publicado: (2020)

Pneumococcal meningitis in adults in 2014–2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan
por: Chang, Bin, et al.
Publicado: (2022)

Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan
por: Kurihara, Erika, et al.
Publicado: (2022)

Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
por: Nakano, Satoshi, et al.
Publicado: (2020)

Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010–2015
por: Silva-Costa, Catarina, et al.
Publicado: (2018)

Global Distribution of Invasive Serotype 35D Streptococcus pneumoniae Isolates following Introduction of 13-Valent Pneumococcal Conjugate Vaccine
por: Lo, Stephanie W., et al.
Publicado: (2018)

Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
por: Southern, Jo, et al.
Publicado: (2018)

Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Causing Invasive Pneumococcal Disease in Korea Between 2017 and 2019 After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine
por: Kim, Gyu Ri, et al.
Publicado: (2023)

1104 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Immunogenicity in the Community Acquired Pneumonia Immunization Trial In Adults (CAPiTA)
por: Van Deursen, Anna M.M., et al.
Publicado: (2014)

The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial
por: Huijts, S.M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s4v7bnba766rifdqc90opv5ad9